These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2042 related items for PubMed ID: 25042855

  • 21. Comparison of combined venous and arterial thrombolysis with primary arterial therapy using recombinant tissue plasminogen activator in acute ischemic stroke.
    Wolfe T, Suarez JI, Tarr RW, Welter E, Landis D, Sunshine JL, Zaidat OO.
    J Stroke Cerebrovasc Dis; 2008; 17(3):121-8. PubMed ID: 18436152
    [Abstract] [Full Text] [Related]

  • 22. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST).
    Wahlgren N, Ahmed N, Eriksson N, Aichner F, Bluhmki E, Dávalos A, Erilä T, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Köhrmann M, Larrue V, Lees KR, Machnig T, Roine RO, Toni D, Vanhooren G, Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy Investigators.
    Stroke; 2008 Dec; 39(12):3316-22. PubMed ID: 18927461
    [Abstract] [Full Text] [Related]

  • 23. Intravenous thrombolysis for acute ischemic stroke associated to extracranial internal carotid artery occlusion: the ICARO-2 study.
    Paciaroni M, Agnelli G, Caso V, Pieroni A, Bovi P, Cappellari M, Zini A, Nichelli P, Inzitari D, Nesi M, Nencini P, Pezzini A, Padovani A, Tassinari T, Orlandi G, Chiti A, Gialdini G, Alberti A, Venti M, Acciarresi M, D'Amore C, Luda E, Tassi R, Martini G, Ferrarese C, Beretta S, Trentini C, Silvestrelli G, Lanari A, Previdi P, Ciccone A, Delodovici ML, Bono G, Galletti G, Marcheselli S, Del Sette M, Traverso E, Riva M, Silvestrini M, Cerqua R, Consoli D, Monaco S, Toni D.
    Cerebrovasc Dis; 2012 Dec; 34(5-6):430-5. PubMed ID: 23207482
    [Abstract] [Full Text] [Related]

  • 24. Combined anti-platelet therapy with aspirin and clopidogrel: risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke?
    Hermann A, Dzialowski I, Koch R, Gahn G.
    J Neurol Sci; 2009 Sep 15; 284(1-2):155-7. PubMed ID: 19473668
    [Abstract] [Full Text] [Related]

  • 25. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.
    Mori M, Naganuma M, Okada Y, Hasegawa Y, Shiokawa Y, Nakagawara J, Furui E, Kimura K, Yamagami H, Kario K, Okuda S, Koga M, Minematsu K, Toyoda K.
    Cerebrovasc Dis; 2012 Sep 15; 34(2):140-6. PubMed ID: 22854333
    [Abstract] [Full Text] [Related]

  • 26. Validation assessment of risk tools to predict outcome after thrombolytic therapy for acute ischemic stroke.
    Van Hooff RJ, Nieboer K, De Smedt A, Moens M, De Deyn PP, De Keyser J, Brouns R.
    Clin Neurol Neurosurg; 2014 Oct 15; 125():189-93. PubMed ID: 25171393
    [Abstract] [Full Text] [Related]

  • 27. Intravenous Tissue Plasminogen Activator for Wake-Up Stroke: A Propensity Score-Matched Analysis.
    Anaissie JE, Monlezun DJ, Siegler JE, Waring ED, Dowell LN, Samai AA, George AJ, Kimbrough T, Berthaud J, Martin-Schild S.
    J Stroke Cerebrovasc Dis; 2016 Nov 15; 25(11):2603-2609. PubMed ID: 27476340
    [Abstract] [Full Text] [Related]

  • 28. Renal Dysfunction Associated with Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis.
    Zhu J, Shen X, Han C, Mei C, Zhou Y, Wang H, Kong Y, Jiang Y, Fang Q, Cai X.
    J Stroke Cerebrovasc Dis; 2019 Nov 15; 28(11):104363. PubMed ID: 31501038
    [Abstract] [Full Text] [Related]

  • 29. Current status of intravenous thrombolysis for acute ischemic stroke in Asia.
    Sharma VK, Ng KW, Venketasubramanian N, Saqqur M, Teoh HL, Kaul S, Srivastava PM, Sergentanis T, Suwanwela N, Nguyen TH, Lawrence Wong KS, Chan BP.
    Int J Stroke; 2011 Dec 15; 6(6):523-30. PubMed ID: 22111797
    [Abstract] [Full Text] [Related]

  • 30. Is there a decreased risk of intracerebral hemorrhage and mortality in obese patients treated with intravenous thrombolysis in acute ischemic stroke?
    Hassan AE, Chaudhry SA, Jani V, Grigoryan M, Khan AA, Adil MM, Qureshi AI.
    J Stroke Cerebrovasc Dis; 2013 May 15; 22(4):545-9. PubMed ID: 23453555
    [Abstract] [Full Text] [Related]

  • 31. Time to recanalization and risk of symptomatic intracerebral haemorrhage in patients treated with intravenous thrombolysis.
    Dorado L, Millán M, Pérez de la Ossa N, Guerrero C, Gomis M, Aleu A, López-Cancio E, Cuadras P, Dávalos A.
    Eur J Neurol; 2012 Sep 15; 19(9):1251-5. PubMed ID: 22568604
    [Abstract] [Full Text] [Related]

  • 32. Predictors of symptomatic intracranial haemorrhage in off-label thrombolysis: an analysis of the Safe Implementation of Treatments in Stroke registry.
    Mundiyanapurath S, Hees K, Ahmed N, Wahlgren N, Uhlmann L, Kieser M, Ringleb PA, Hacke W, Nagel S.
    Eur J Neurol; 2018 Feb 15; 25(2):340-e11. PubMed ID: 29105904
    [Abstract] [Full Text] [Related]

  • 33. Defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the National Institute of Neurological Disorders and Stroke tissue-type plasminogen activator trials.
    Rao NM, Levine SR, Gornbein JA, Saver JL.
    Stroke; 2014 Sep 15; 45(9):2728-33. PubMed ID: 25096731
    [Abstract] [Full Text] [Related]

  • 34. Computed Tomography--Verified Leukoaraiosis Is a Risk Factor for Post-thrombolytic Hemorrhage.
    Willer L, Havsteen I, Ovesen C, Christensen AF, Christensen H.
    J Stroke Cerebrovasc Dis; 2015 Jun 15; 24(6):1126-30. PubMed ID: 25920756
    [Abstract] [Full Text] [Related]

  • 35. Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
    Cheng JW, Zhang XJ, Cheng LS, Li GY, Zhang LJ, Ji KX, Zhao Q, Bai Y.
    J Stroke Cerebrovasc Dis; 2018 Feb 15; 27(2):381-390. PubMed ID: 29111341
    [Abstract] [Full Text] [Related]

  • 36. Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset.
    Diedler J, Ahmed N, Sykora M, Uyttenboogaart M, Overgaard K, Luijckx GJ, Soinne L, Ford GA, Lees KR, Wahlgren N, Ringleb P.
    Stroke; 2010 Feb 15; 41(2):288-94. PubMed ID: 20056933
    [Abstract] [Full Text] [Related]

  • 37. Safety of intravenous thrombolysis in acute ischemic stroke patients with saccular intracranial aneurysms.
    Mittal MK, Seet RC, Zhang Y, Brown RD, Rabinstein AA.
    J Stroke Cerebrovasc Dis; 2013 Jul 15; 22(5):639-43. PubMed ID: 22341666
    [Abstract] [Full Text] [Related]

  • 38. Thrombolysis with alteplase for acute ischemic stroke: review of SITS-MOST and other Phase IV studies.
    Külkens S, Hacke W.
    Expert Rev Neurother; 2007 Jul 15; 7(7):783-8. PubMed ID: 17610385
    [Abstract] [Full Text] [Related]

  • 39. Risk of thrombolytic therapy for acute ischemic stroke in patients with current malignancy.
    Masrur S, Abdullah AR, Smith EE, Hidalgo R, El-Ghandour A, Rordorf G, Schwamm LH.
    J Stroke Cerebrovasc Dis; 2011 Jul 15; 20(2):124-30. PubMed ID: 20598579
    [Abstract] [Full Text] [Related]

  • 40. Chronic kidney disease and bleeding complications after intravenous thrombolytic therapy for acute ischemic stroke.
    Ovbiagele B, Smith EE, Schwamm LH, Grau-Sepulveda MV, Saver JL, Bhatt DL, Hernandez AF, Peterson ED, Fonarow GC.
    Circ Cardiovasc Qual Outcomes; 2014 Nov 15; 7(6):929-35. PubMed ID: 25249561
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 103.